• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CeriBell Inc.

    2/25/25 5:29:53 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email
    S-8 1 cbll-20250225.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on February 25, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    CeriBell, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

     

    47-1785452

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

     

    360 N. Pastoria Avenue

    Sunnyvale, California

     

    94085

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    CeriBell, Inc. 2024 Incentive Award Plan

    CeriBell, Inc. 2024 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Jane Chao, Ph.D.

    President, Chief Executive Officer, and Co-Founder

    CeriBell, Inc.

    360 N. Pastoria Avenue

    Sunnyvale, California 94085

    (800) 436-0826

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Kathleen M. Wells

    John C. Williams

    Richard Kim

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    Telephone: (650) 328-4600

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

     

    ☐

     

    Accelerated filer

     

    ☐

     

     

     

     

    Non-accelerated filer

     

    ☒

     

    Smaller reporting company

     

    ☒

     

     

     

     

     

     

     

     

    Emerging growth company

     

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

     

    EXPLANATORY NOTE

     

    CeriBell, Inc., a Delaware corporation (the “Registrant”) is filing this Registration Statement on Form S-8 to register an additional 2,151,036 shares of its common stock, par value $0.001 (“Common Stock”) issuable under the Registrant's (i) 2024 Incentive Award Plan (the “2024 Plan”) and (ii) 2024 Employee Stock Purchase Plan (the “ESPP”). As a result of the operation of annual increase provisions therein, 1,792,530 shares of common stock were added to the 2024 Plan and 358,506 shares of common stock were added to the ESPP.

     

    On October 11, 2024, the Registrant filed with the U.S. Securities and Exchange Commission (the “Commission”) a Registration Statement on Form S-8 (File No. 333-282603) (the “Prior Registration Statement”) relating to shares of Common Stock issuable to eligible employees, consultants, and directors of the Registrant under the 2024 Plan and the ESPP. The Prior Registration Statement is currently effective. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statement relates and is submitted in accordance with General Instruction E of Form S-8 regarding the “Registration of Additional Securities.”

     

    Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statement relating to the 2024 Plan and the ESPP, including periodic reports that the Registrant filed after the Prior Registration Statement to maintain current information about the Registrant, are incorporated herein by reference and made part of this Registration Statement, except to the extent supplemented, superseded, or modified by the specific information set forth below and/or the specific exhibits attached hereto.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Not required to be filed with this Registration Statement.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

     

     

     

     

     

     

     

     

     

     

    Exhibit

     

    Exhibit Description

     

    Incorporated by Reference

     

    Filed

    Number

     

     

    Form

     

    Date

     

    Number

     

    Herewith

    4.1

     

    Amended and Restated Certificate of Incorporation

     

    8-K

     

    10/15/24

     

    3.1

     

     

    4.2

     

    Amended and Restated Bylaws

     

    8-K

     

    10/15/24

     

    3.2

     

     

    4.3

     

    Form of Common Stock Certificate.

     

    S-1/A

     

    9/19/24

     

    4.01

     

     

    5.1

     

    Opinion of Latham & Watkins LLP.

     

     

     

     

     

     

     

    X

    23.1

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

    X

    23.2

     

    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.

     

     

     

     

     

     

     

    X

    24.1

     

    Power of Attorney. Reference is made to the signature page to the Registration Statement.

     

     

     

     

     

     

     

    X

    99.1#

     

    2024 Incentive Award Plan.

     

    S-1/A

     

    10/7/24

     

    10.14

     

     

    99.2#

     

    Form of Agreements under 2024 Incentive Award Plan.

     

    S-1/A

     

    10/7/24

     

    10.15

     

     

    99.3#

     

    2024 Employee Stock Purchase Plan.

     

    S-1/A

     

    10/7/24

     

    10.16

     

     

    107

     

    Calculation of Filing Fee Table.

     

     

     

     

     

     

     

    X

     

    #  Indicates management contract or compensatory plan.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sunnyvale, State of California, on this 25th day of February, 2025.

    CeriBell, Inc.

     

     

    By:

     

    /s/ Xingjuan (Jane) Chao, Ph.D.

     

     

    Xingjuan (Jane) Chao, Ph.D.

     

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Xingjuan (Jane) Chao, Ph.D., Scott Blumberg, and Louisa Daniels, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

    /s/ Xingjuan (Jane) Chao, Ph.D.

    Xingjuan (Jane) Chao, Ph.D.

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    February 25, 2025

     

     

     

    /s/ Scott Blumberg

    Scott Blumberg

     

    Chief Financial Officer

    (Principal Financial Officer)

     

    February 25, 2025

     

     

     

    /s/ David Foehr

    David Foehr

     

    Senior Vice President, Finance

    (Principal Accounting Officer)

     

    February 25, 2025

     

     

     

    /s/ Rebecca (Beckie) Robertson

    Rebecca (Beckie) Robertson

     

    Director

     

    February 25, 2025

     

     

     

    /s/ Juliet Tammenoms Bakker

    Juliet Tammenoms Bakker

     

    Director

     

    February 25, 2025

     

     

     

    /s/ William W. Burke

    William W. Burke

     

    Director

     

    February 25, 2025

     

     

     

    /s/ Lucian Iancovici, M.D.

    Lucian Iancovici, M.D.

     

    Director

     

    February 25, 2025

     

     

     

    /s/ Joseph M. Taylor

    Joseph M. Taylor

     

    Director

     

    February 25, 2025

     

     

     

     

     

    /s/ Josef Parvizi

     

    Director

     

    February 25, 2025

    Josef Parvizi, M.D., Ph.D.

     

     

     

     


    Get the next $CBLL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    10/21/2025$19.00Strong Buy
    Raymond James
    6/24/2025$30.00Buy
    BTIG Research
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings

    $CBLL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by CeriBell Inc.

    SCHEDULE 13G/A - Ceribell, Inc. (0001861107) (Subject)

    2/5/26 1:20:38 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CeriBell Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ceribell, Inc. (0001861107) (Filer)

    1/5/26 10:53:59 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CeriBell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Ceribell, Inc. (0001861107) (Filer)

    1/2/26 4:45:27 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tpg Gp A, Llc converted options into 3,587,154 shares and bought $6,464,556 worth of shares (380,268 units at $17.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    10/17/24 4:14:38 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Tammenoms Bakker Juliet was granted 6,618 shares, converted options into 2,140,600 shares and bought $4,032,978 worth of shares (237,234 units at $17.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    10/16/24 4:18:06 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on CeriBell with a new price target

    Raymond James initiated coverage of CeriBell with a rating of Strong Buy and set a new price target of $19.00

    10/21/25 7:19:41 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BTIG Research initiated coverage on CeriBell with a new price target

    BTIG Research initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00

    6/24/25 8:00:31 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ladenburg Thalmann initiated coverage on CeriBell with a new price target

    Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00

    4/4/25 8:27:23 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Diagnostics: The End of the High-Cost Imaging Era

    VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) --  Equity-Insider.com News Commentary – The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034[1]. This systemic re-rating is driven by healthcare's structural pivot from bulky, expensive hardware to agile, software-defined intelligence. As diagnostics move out of specialized labs and into decentralized, point-of-care environments[2], institutions are rotating capital into a first-mover cohort capable of delivering MRI-grade accuracy on the fly. This secular transition is positioning VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Heartflow (NASDAQ:HTFL), AtriCure (NASDAQ:ATRC), Edwards

    1/16/26 11:40:51 AM ET
    $ATRC
    $CBLL
    $EW
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Industrial Specialties

    Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution

    SUNNYVALE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor for patients in the hospital setting. This first-in-class LVO stroke detection monitor uses Ceribell's existing hardware and applies an AI-based algorithm to interpret EEG signals for early detection of LVO stroke. The Breakthrough Device Designation for LVO Stroke represents the latest achievemen

    1/5/26 8:00:00 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    SUNNYVALE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 9:00 am Pacific Standard Time / 12:00 pm Eastern Standard Time.  Event: 44th Annual J.P. Morgan Healthcare ConferenceDate: Monday, January 12, 2026Time: 9:00 am PST / 12:00 pm EST A live and archived webcast of the presentation will be available in th

    12/30/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Chao Xingjuan sold $786,240 worth of shares (39,000 units at $20.16) and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 727,248 units (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    2/6/26 3:51:31 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Senior VP, Finance and PAO Foehr David exercised 5,556 shares at a strike of $4.70 and sold $111,120 worth of shares (5,556 units at $20.00) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    2/5/26 12:54:22 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Technology Officer Woo Raymond exercised 11,112 shares at a strike of $4.37 and sold $228,375 worth of shares (11,112 units at $20.55) (SEC Form 4)

    4 - Ceribell, Inc. (0001861107) (Issuer)

    2/4/26 4:01:25 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Leadership Updates

    Live Leadership Updates

    View All

    Medtech Leader Erica Rogers Joins Ceribell Board of Directors

    SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell's Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting. Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently

    9/22/25 8:00:03 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing

    —Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu

    11/19/24 8:00:00 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Financials

    Live finance-specific insights

    View All

    Ceribell Reports Third Quarter 2025 Financial Results

    SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared to 87% for the same period in 2024 Ended the quarter with 615 total active accounts Appointed Erica Rogers to the Board of Directors "We are encouraged by our third quarter performance, which re

    11/4/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025

    SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 93946

    10/21/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Ceribell Reports Second Quarter 2025 Financial Results

    SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the second quarter of 2025Ended the quarter with 584 total active accounts  "We are pleased with our second quarter results, which reflect our successful commercial execution as we accelerate adopt

    8/5/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CBLL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CeriBell Inc.

    SC 13G - Ceribell, Inc. (0001861107) (Subject)

    11/7/24 9:24:55 AM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by CeriBell Inc.

    SC 13D - Ceribell, Inc. (0001861107) (Subject)

    10/22/24 4:20:26 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care